Automatic Website Traffic RSS

CAR-T Cell Therapy: Will First To Market Mean First To Disappoint ...

Gilead and Novartis have launched the first two autologous CAR-T cell therapies. Combined, their first year revenues were less than $250 million. read more

Researchers link CAR-T cell aging to cancer relapse

Mayo Clinic researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T-cell therapy, or CAR-T cell therapy. Over time, the engineered immune ... read more

New CAR-T cell therapy 'ALA-CART' shows promise for hard-to-treat ... - MSN

CAR-T cell therapy involves extracting a patient's T-cells, modifying them to recognize cancer cells, and then reinfusing them into the patient where they target cancer cells throughout the body. read more

Iovance sinks as pivotal cell therapy data disappoint investors

TIL (today I learned) that now is not the time to disappoint investors. | Iovance Biotherapeutics trumpeted a 29% response rate and a 10.4-month median duration of response in a pivotal advanced ... read more

CAR-T Cell Therapy Market Research 2024-2025: Navigating the CAR-T ...

CAR-T cell therapy is a remarkably promising treatment for cancer patients. It is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the ... read more

FDA requires new warning for Penn-pioneered CAR-T therapy products

The first CAR-T therapy — which was manufactured by Novartis — was approved by the FDA in 2017 for the treatment of pediatric and young adult patients with B-cell acute lymphoblastic leukemia. "I have ... read more

Designer immune-cell therapy could shrink deadly brain tumors, early ...

Two early clinical trials that together included nine patients suggest that a treatment called CAR-T therapy could treat glioblastoma, but its long-term effects are unknown. read more

First Patients Dosed in WU-CART-007 Trial for Blood Cancer Subtypes

The first patients have been dosed in a trial of CAR T therapy in relapsed/refractory T cell acute lymphoblastic leukemia or T cell lymphoblastic lymphoma. read more

Wugen Announces Dosing of First Patients in Pivotal Trial of Off-the ...

"WU-CART-007 has shown clinical response and manageable safety, making it a promising off-the-shelf cell therapy candidate to fill a longstanding treatment gap. read more

Bristol Myers Squibb wins first CAR-T therapy approval in multiple ...

The FDA has approved a Bristol Myers Squibb cell therapy made by engineering a patient’s immune cells to target a cancer protein called BCMA. The regulatory decision for Abecma in multiple ... read more